National Clinical Research Center for Hematologic Diseases, Cyrus Tang Medical Institute, Collaborative Innovation Center of Hematology, State Key Laboratory of Radiation Medicine and Prevention, Soochow University, Suzhou 215123, China.
College of Medical Technology, Taizhou Polytechnic College, Taizhou 225300, China.
Proc Natl Acad Sci U S A. 2021 Jun 1;118(22). doi: 10.1073/pnas.2020057118.
The immunosuppressive and hypoxic tumor microenvironment (TME) remains a major obstacle to impede cancer immunotherapy. Here, we showed that elevated levels of Delta-like 1 (DLL1) in the breast and lung TME induced long-term tumor vascular normalization to alleviate tumor hypoxia and promoted the accumulation of interferon γ (IFN-γ)-expressing CD8 T cells and the polarization of M1-like macrophages. Moreover, increased DLL1 levels in the TME sensitized anti-cytotoxic T lymphocyte-associated protein 4 (anti-CTLA4) treatment in its resistant tumors, resulting in tumor regression and prolonged survival. Mechanically, in vivo depletion of CD8 T cells or host IFN-γ deficiency reversed tumor growth inhibition and abrogated DLL1-induced tumor vascular normalization without affecting DLL1-mediated macrophage polarization. Together, these results demonstrate that elevated DLL1 levels in the TME promote durable tumor vascular normalization in a CD8 T cell- and IFN-γ-dependent manner and potentiate anti-CTLA4 therapy. Our findings unveil DLL1 as a potential target to persistently normalize the TME to facilitate cancer immunotherapy.
免疫抑制和缺氧的肿瘤微环境(TME)仍然是阻碍癌症免疫治疗的主要障碍。在这里,我们表明,乳腺和肺部 TME 中 Delta-like 1(DLL1)水平的升高诱导了长期的肿瘤血管正常化,从而减轻了肿瘤缺氧,并促进了干扰素 γ(IFN-γ)表达的 CD8 T 细胞的积累和 M1 样巨噬细胞的极化。此外,TME 中 DLL1 水平的增加使对细胞毒性 T 淋巴细胞相关蛋白 4(抗 CTLA4)治疗的耐药肿瘤变得敏感,导致肿瘤消退和生存时间延长。在体内,耗尽 CD8 T 细胞或宿主 IFN-γ 缺乏会逆转肿瘤生长抑制并消除 DLL1 诱导的肿瘤血管正常化,而不影响 DLL1 介导的巨噬细胞极化。总之,这些结果表明,TME 中升高的 DLL1 水平以 CD8 T 细胞和 IFN-γ 依赖的方式促进持久的肿瘤血管正常化,并增强抗 CTLA4 治疗。我们的研究结果表明,DLL1 是一个潜在的靶点,可以持续使 TME 正常化,从而促进癌症免疫治疗。